兒童臨床試驗市場－全球產業規模、佔有率、趨勢、機會和預測：按階段、研究設計、治療領域、地區和競爭格局分類，2021-2031年

全球兒童臨床試驗市場預計將從 2025 年的 161.1 億美元成長到 2031 年的 254.5 億美元，複合年成長率為 7.92%。

該市場涵蓋評估從嬰兒期到18歲各年齡層治療藥物安全性和有效性的研究。推動這一市場擴張的關鍵因素包括：嚴格的監管要求強制要求對新藥進行兒童評估，以及業界對罕見遺傳疾病治療日益成長的興趣。根據美國製藥商協會（PhRMA）預測，到2025年，將有超過560種針對兒童罕見疾病的新治療方法正在開發平臺中，這一因素正持續推動整個產業的投資和研發投入。

儘管存在這些積極因素，但患者招募仍然是一項重大挑戰，可能會減緩市場成長。符合條件的受試者數量有限，加上知情同意嚴格的倫理標準，常常導致研究週期延長和成本增加。因此，難以獲得足夠的患者以獲得具有統計意義的可靠數據，這仍然是製藥公司和合約研究組織（CRO）面臨的持續性障礙，並可能阻礙兒童治療藥物的及時研發。

市場促進因素

擴大的財政獎勵和市場壟斷條款正成為市場擴張的關鍵催化劑，尤其是透過諸如罕見兒童疾病優先審評券（PRV）計畫等措施。這些監管機制正在將成功的兒童藥物研發轉化為寶貴的商業性資產，並鼓勵研發人員將目標鎖定在規模較小、盈利通常較低的患者群體。近年來，這些獎勵的貨幣化潛力激增，催生了一個競爭激烈的二級市場，用於交易能夠抵消高昂研發成本的優先審查券。 2025年3月，Biospace報道稱，受大型製藥公司對其旗艦產品加快審查的需求推動，這些優先審查券的交易價格在年初達到了1.5億美元。這使得中小型生物技術公司能夠獲得即時資金並降低財務風險。

同時，罕見疾病和兒童罕見疾病研發投入的顯著成長正在改變臨床格局。業界正充分利用這些特殊認定所帶來的高監管核准成功率。各公司越來越重視那些尚未充分滿足的細分適應症，因為孤兒藥療法比標準療法更容易獲得核准。根據 Norm Bio（2025 年 11 月）預測，孤兒藥的核准將達到 25-30%，遠高於傳統藥物 10-12% 的成功率。美國製藥商協會 (PhRMA) 的數據也反映了這個策略重點。 PhRMA 於 2025 年 10 月宣布，目前有超過 2,100 項由業界主導的兒童臨床試驗正在進行中，涉及 120 萬名患者，這凸顯了業界對複雜兒童疾病的重視。

市場挑戰

病患招募困難造成了營運瓶頸，導致研究完成時間延長，研發成本增加，嚴重阻礙了全球兒童臨床試驗市場的成長。合格的兒童受試者短缺，加上嚴格的知情同意倫理要求，常常導致試驗無法在計畫時間內達到招募目標。當製藥公司無法快速收集足夠的數據時，整個開發平臺都會被延誤，從而抑制未來對兒童特定適應症的投資，並限制整體市場規模。

近期行業調查結果也印證了這種營運效率低下的問題。根據臨床研究專業人員協會 (ACRP) 的數據，到 2024 年，36% 的臨床研究機構將把病患招募和留存列為一項主要的營運挑戰。由於兒科患者群體規模較小且地理分佈更為分散，因此兒童研究領域的問題更為嚴峻。由此，無法有效率地招募受試者會直接導致試驗週期延長，增加申辦者的財務風險，從而阻礙市場成長，並促使申辦方在啟動新的兒童研究時採取更為謹慎的態度。

市場趨勢

人工智慧 (AI) 在精準隊列識別方面的應用，正從根本上改變患者選擇策略，使其從人工篩檢轉向對電子健康記錄進行演算法分析。這項技術整合使申辦方能夠透過處理傳統方法常常忽略的非結構化臨床記錄和遺傳標記，快速識別合格的兒童受試者。透過從海量資料集中自動檢測特定的納入標準，製藥研發公司可以減少因合格受試者短缺而導致的營運延誤。美國國立衛生研究院 (NIH) 於 2024 年 6 月發布的題為《人工智慧在兒童臨床試驗中的應用》的報告指出，在兒童腫瘤試驗中使用的 AI 演算法可將患者篩檢工作量減少高達 90%，並顯著加快合格候選者的識別速度。

同時，用於遠距兒童監測的穿戴式設備的普及，透過最大限度地減少侵入性就診的需求，提高了資料完整性和參與者保留率。這些非侵入性工具能夠在兒童的自然環境中持續收集生理生物標記物，減輕家庭負擔，並確保長期研究的持續參與。這種轉變提高了所收集的真實世界數據的質量，並支持以患者為中心的、針對兒童人群需求的個人化方法。根據臨床研究專業人員協會 (ACRP) 於 2024 年 10 月發表的題為「利用穿戴式數位健康技術增強臨床試驗」的報導，採用穿戴式技術的試驗已實現了 70% 至 80% 的高患者依從率，證明了其在維持通訊協定依從性方面的有效性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球兒童臨床試驗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 階段（第一階段、第二階段、第三階段、第四階段）
  • 按研究設計（治療性研究和觀察性研究）
  • 依治療領域（呼吸系統疾病、感染疾病、腫瘤、糖尿病及其他治療領域）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美兒童臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲兒童臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區兒童臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲兒童臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲兒童臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球兒童臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pediatric Clinical Trials Market is projected to experience significant growth, rising from USD 16.11 Billion in 2025 to USD 25.45 Billion by 2031, reflecting a CAGR of 7.92%. This market encompasses research studies designed to assess the safety and efficacy of medical treatments specifically for the population aged from birth to 18 years. Primary factors driving this expansion include stringent regulatory mandates that require pediatric assessments for new medications and a heightened industry focus on treating rare genetic disorders. According to the Pharmaceutical Research and Manufacturers of America, there were over 560 novel therapies for rare diseases-which disproportionately impact children-in the development pipeline in 2025, a factor that continues to stimulate investment and research across the sector.

Despite these positive indicators, patient recruitment remains a formidable challenge that threatens to slow market growth. The restricted number of eligible participants, combined with rigorous ethical standards regarding informed consent, frequently results in prolonged timelines and escalating costs. Consequently, the difficulty in securing adequate enrollment to produce statistically robust data serves as a persistent obstacle for pharmaceutical companies and contract research organizations, potentially hindering the timely development of pediatric therapies.

Market Driver

The broadening of financial incentives and market exclusivity provisions serves as a major catalyst for market expansion, particularly through initiatives such as the Rare Pediatric Disease Priority Review Voucher (PRV) program. These regulatory mechanisms transform successful pediatric drug development into valuable commercial assets, encouraging developers to target smaller, often less profitable patient groups. The monetization potential of these incentives has surged recently, fostering a competitive secondary market for vouchers that helps subsidize high research costs. BioSpace reported in March 2025 that the trading price for these vouchers reached $150 million early in the year, driven by demand from major pharmaceutical firms seeking expedited review for flagship products, thereby providing immediate capital to smaller biotech firms and reducing financial risks.

Simultaneously, a significant increase in R&D for rare and orphan pediatric disorders is reshaping the clinical landscape, as the industry leverages the higher regulatory success rates associated with these special designations. Companies are increasingly prioritizing niche indications with high unmet needs, utilizing the fact that orphan-designated therapies often navigate approval processes more efficiently than standard treatments. According to Nome Bio in November 2025, orphan-designated products are achieving approval rates of 25-30%, significantly outperforming the 10-12% success rate of conventional drugs. This strategic focus is reflected in data from the Pharmaceutical Research and Manufacturers of America (PhRMA), which noted in October 2025 that over 2,100 industry-sponsored pediatric trials involving 1.2 million patients are currently underway, highlighting the sector's commitment to complex pediatric conditions.

Market Challenge

Difficulties regarding patient recruitment significantly hinder the growth of the Global Pediatric Clinical Trials Market by causing operational bottlenecks that delay study completion and increase development costs. The scarcity of eligible pediatric subjects, exacerbated by strict ethical requirements for informed consent, often leads to trials failing to meet enrollment targets within planned schedules. When pharmaceutical companies are unable to gather sufficient data promptly, the entire development pipeline slows, which discourages future investment in pediatric-specific indications and limits overall market volume.

This operational inefficiency is supported by recent industry findings. Data from the Association of Clinical Research Professionals indicates that in 2024, 36% of clinical research sites cited patient recruitment and retention as their primary operational challenge. This issue is even more acute in pediatric research, where patient pools are naturally smaller and more geographically dispersed than in adult populations. Consequently, the inability to efficiently enroll participants directly impedes market growth by extending trial durations and increasing financial risks for sponsors, resulting in a more cautious approach toward initiating new pediatric studies.

Market Trends

The adoption of Artificial Intelligence for Precise Cohort Identification is fundamentally transforming patient selection strategies by moving from manual screening to the algorithmic analysis of electronic health records. This technological integration enables sponsors to swiftly identify eligible pediatric participants by processing unstructured clinical notes and genetic markers that traditional methods might miss. By automating the detection of specific inclusion criteria across vast datasets, pharmaceutical developers can alleviate operational delays caused by the shortage of eligible subjects. A June 2024 report by the National Institutes of Health, titled 'Applying Artificial Intelligence in Pediatric Clinical Trials,' noted that AI algorithms used in pediatric oncology trials reduced the patient screening workload by up to 90%, significantly accelerating the identification of suitable candidates.

In parallel, the increasing use of Wearable Devices for Remote Pediatric Monitoring is enhancing data integrity and participant retention by minimizing the need for intrusive on-site visits. These non-invasive tools allow for the continuous collection of physiological biomarkers in the child's natural environment, thereby reducing the logistical burden on families and ensuring consistent engagement during long-term studies. This shift improves the quality of real-world evidence gathered and supports a patient-centric approach aligned with the needs of pediatric populations. According to the Association of Clinical Research Professionals in October 2024, in the 'Enhancing Clinical Trials with Wearable Digital Health Technologies' article, trials incorporating wearable technologies achieved high patient adherence rates between 70% and 80%, demonstrating their effectiveness in maintaining protocol compliance.

Key Market Players

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

Report Scope

In this report, the Global Pediatric Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• and Phase IV

Pediatric Clinical Trials Market, By Study Design

• Treatment Studies and Observational Studies

Pediatric Clinical Trials Market, By Therapeutic Area

• Respiratory Diseases
• Infectious Diseases
• Oncology
• Diabetes
• and Other Therapeutic Areas

Pediatric Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.

Available Customizations:

Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
  • 5.2.2. By Study Design (Treatment Studies and Observational Studies)
  • 5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Therapeutic Area
  • 6.3.2. Canada Pediatric Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Therapeutic Area
  • 6.3.3. Mexico Pediatric Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Therapeutic Area

7. Europe Pediatric Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Therapeutic Area
  • 7.3.2. France Pediatric Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Therapeutic Area
  • 7.3.3. United Kingdom Pediatric Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Therapeutic Area
  • 7.3.4. Italy Pediatric Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Therapeutic Area
  • 7.3.5. Spain Pediatric Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Therapeutic Area

8. Asia Pacific Pediatric Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Therapeutic Area
  • 8.3.2. India Pediatric Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Therapeutic Area
  • 8.3.3. Japan Pediatric Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Therapeutic Area
  • 8.3.4. South Korea Pediatric Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Therapeutic Area
  • 8.3.5. Australia Pediatric Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Therapeutic Area

9. Middle East & Africa Pediatric Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Therapeutic Area
  • 9.3.2. UAE Pediatric Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Therapeutic Area
  • 9.3.3. South Africa Pediatric Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Therapeutic Area

10. South America Pediatric Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Therapeutic Area
  • 10.3.2. Colombia Pediatric Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Therapeutic Area
  • 10.3.3. Argentina Pediatric Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Charles River Laboratories International Inc.
• 15.3. Covance Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. ICON plc
• 15.6. IQVIA Inc.
• 15.7. Novartis AG
• 15.8. Pfizer, Inc.
• 15.9. Pharmaceutical Product Development, LLC
• 15.10. Syneos Health Inc.
• 15.11. Paidion Research, Inc.
• 15.12. The Emmes Company, LLC

16. Strategic Recommendations

17. About Us & Disclaimer